Catalyst Dossier · compiled by CeliA 🧫

Galderma Group AG/ADR (GALDY)

Biotechnology · market cap $50.4B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Galderma Group AG/ADR (GALDY) is a dermatology-focused company with a market cap of approximately $50.4 billion and a broad clinical pipeline spanning acne, rosacea, actinic keratoses, psoriasis, and aesthetics (botulinum toxins). The most imminent catalysts are three Phase 3 readouts for nemolizumab in Prurigo Nodularis, estimated between August and October 2026, plus a Phase 3 vehicle cream readout in December 2026. No recent catalysts have been reported and no analyst consensus or financial detail is publicly available in the provided facts.

The catalyst path

2026-08-31 (est.)Phase 3 · Nemolizumabimp 9/10
2026-09-15 (est.)Phase 2 · Nemolizumabimp 7/10
2026-10-26 (est.)Phase 3 · Nemolizumabimp 9/10

Pipeline

Asset	Phase	Indication
MAL 16.8% cream	Phase 3	Actinic Keratoses
Metvix and natural daylight PDT	Phase 3	Actinic Keratoses
Adapalene BPO Gel standard daily overnight application	Phase 3	Acne
botulinum toxin neuromodulator	Phase 3	Glabellar Lines
Metvix Cream 160 mg/g	Phase 2	Photoaged Skin
Epiduo vehicle gel	Phase 2	Acne
OnabotulinumtoxinA	Phase 3	Moderate to Severe Glabellar Lines
Azelaic acid 15% Gel	Phase 3	Papulopustular Rosacea (PPR)
CD5789 (trifarotene)	Phase 3	Acne Vulgaris
Calcitriol 3mcg/g	Phase 2	Chronic Plaque Psoriasis
CD14152 Dose A	Phase 2	Prurigo Nodularis
AbobotulinumtoxinA	Phase 3	Glabellar Frown Lines
Adapalene Lotion Vehicle	Phase 3	Acne Vulgaris
CD5024 0.3% cream	Phase 2	Atopic Dermatitis
CD11301 0.03%	Phase 2	Cutaneous T Cell Lymphoma
CD0271	Phase 3	Acne Vulgaris
0.18% COL-118 facial gel (1.8 mg brimonidine)	Phase 2	Erythematous Rosacea
Metvix cream	Phase 3	Basal Cell Carcinoma
CD5789 (trifarotene) 50μg/g cream	Phase 3	Acne Vulgaris
C. propionate - Corticosteroid 1	Phase 3	Scalp Psoriasis

Price & technical context

3-month

-2.4%

6-month

+3.5%

12-month

+68.9%

52-wk range

$23.91–$43.92

vs 50-day MA

-0.9%

vs 200-day MA

+3.4%

Realized vol

33.1%

Max drawdown

-67.1%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GALDY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.